CRISPR-mediated genome editing tools are entering the clinic, but concerns remain about the potential immunogenicity of these bacterial-derived proteins. Here, Raghavan et al. engineer two Cas effectors, Cas9 and Cas12, for reduced immunogenicity in vivo while maintaining on-target activity.
- Rumya Raghavan
- Mirco J. Friedrich
- Feng Zhang